标题
The emerging safety profile of JAK inhibitors in rheumatic disease
作者
关键词
-
出版物
Nature Reviews Rheumatology
Volume 13, Issue 4, Pages 234-243
出版商
Springer Nature
发表日期
2017-03-02
DOI
10.1038/nrrheum.2017.23
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
- (2016) Munther Khamashta et al. ANNALS OF THE RHEUMATIC DISEASES
- THU0185 Tofacitinib, An Oral JAK Inhibitor, in The Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years
- (2016) J. Wollenhaupt et al. ANNALS OF THE RHEUMATIC DISEASES
- SP0104 Neutrophils in The Resolution of Inflammation
- (2016) M. Herrmann ANNALS OF THE RHEUMATIC DISEASES
- SP0097 Intracellular MTX Polyglutamates and Clinical Response
- (2016) R. de Jonge ANNALS OF THE RHEUMATIC DISEASES
- Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
- (2016) Jeffrey R Curtis et al. ANNALS OF THE RHEUMATIC DISEASES
- Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
- (2016) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- Baricitinib in Patients with Refractory Rheumatoid Arthritis
- (2016) Mark C. Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- (2016) Mark C. Genovese et al. Arthritis & Rheumatology
- A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy
- (2016) Joel M. Kremer et al. Arthritis & Rheumatology
- Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments
- (2016) Fenglong Xie et al. Arthritis & Rheumatology
- Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance
- (2015) K L Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- THU0173 Pregnancy Outcomes in the Tofacitinib RA Safety Database Through April 2014
- (2015) A. Marren et al. ANNALS OF THE RHEUMATIC DISEASES
- SP0027 One for All – Patient Research Partners Involved in Disseminating Eular Recommendations Among Belgium Patients
- (2015) I. De Keyser ANNALS OF THE RHEUMATIC DISEASES
- OP0025-PARE Campaign Against the Shortage of Rheumatology Professionals
- (2015) M. Ekroth et al. ANNALS OF THE RHEUMATIC DISEASES
- Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
- (2015) K L Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
- (2015) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
- (2015) Jeffrey R Curtis et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
- (2015) Himal Lal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
- (2015) Jasvinder A. Singh et al. ARTHRITIS CARE & RESEARCH
- Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial
- (2015) Joel M Kremer et al. ARTHRITIS RESEARCH & THERAPY
- A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
- (2015) Roy M. Fleischmann et al. Arthritis & Rheumatology
- VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- Long-term Persistence of Zoster Vaccine Efficacy
- (2014) Vicki A. Morrison et al. CLINICAL INFECTIOUS DISEASES
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
- (2014) James D. Clark et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
- (2014) J. Wollenhaupt et al. JOURNAL OF RHEUMATOLOGY
- Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis
- (2014) Chul Won Jung et al. LEUKEMIA & LYMPHOMA
- Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
- (2014) Stanley Cohen et al. Arthritis & Rheumatology
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
- (2014) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials
- (2013) V P Bykerk et al. ANNALS OF THE RHEUMATIC DISEASES
- 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
- (2013) Lorry G. Rubin et al. CLINICAL INFECTIOUS DISEASES
- Association Between the Initiation of Anti–Tumor Necrosis Factor Therapy and the Risk of Herpes Zoster
- (2013) Kevin L. Winthrop et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program
- (2013) M. E. Weinblatt et al. JOURNAL OF RHEUMATOLOGY
- Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
- (2013) M. C. Genovese et al. JOURNAL OF RHEUMATOLOGY
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
- (2013) Cem Gabay et al. LANCET
- Back to the future: oral targeted therapy for RA and other autoimmune diseases
- (2013) John J. O'Shea et al. Nature Reviews Rheumatology
- Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib
- (2013) Rowan Wathes et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAKs and STATs in Immunity, Immunodeficiency, and Cancer
- (2013) John J. O'Shea et al. NEW ENGLAND JOURNAL OF MEDICINE
- Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160
- (2012) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
- (2012) Ronald F van Vollenhoven et al. ANNALS OF THE RHEUMATIC DISEASES
- Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
- (2012) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
- (2012) John J. O'Shea et al. IMMUNITY
- Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care Plans
- (2011) Gabriela Schmajuk et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Type I interferon is selectively required by dendritic cells for immune rejection of tumors
- (2011) Mark S. Diamond et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Varicella Zoster Virus DNA at Inoculation Sites and in Saliva After Zostavax Immunization
- (2011) Duane L. Pierson et al. JOURNAL OF INFECTIOUS DISEASES
- Functional Correlations of Pathogenesis-Driven Gene Expression Signatures in Tuberculosis
- (2011) Jeroen Maertzdorf et al. PLoS One
- Rheumatoid arthritis and herpes zoster: risk and prevention in those treated with anti-tumour necrosis factor therapy
- (2010) K. L. Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- Identification of a Potent Janus Kinase 3 Inhibitor with High Selectivity within the Janus Kinase Family
- (2010) Gebhard Thoma et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data
- (2010) Johan Askling et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- A partial form of recessive STAT1 deficiency in humans
- (2009) Ariane Chapgier et al. JOURNAL OF CLINICAL INVESTIGATION
- Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment
- (2008) T A Simon et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Cytokine Signaling Modules in Inflammatory Responses
- (2008) John J. O'Shea et al. IMMUNITY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now